Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
Condition(s) studied
Investigational drug(s) / intervention(s)
Telemedicine Buprenorphine Treatment: With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors.
Study summary
Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.
Eligibility
Primary outcome measure(s)
- Intervention Acceptability, Appropriateness, Feasibility — 48 weeks
To measure the participant intervention experience, the study team will utilize qualitative interview data with study participants. These data will be organized into the implementation science categories: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). The study team will determine whether each participant found the intervention to be feasible, acceptable, and/or appropriate. These findings will then be aggregated to better understand how participants experience the implementation of a telemedicine Opioid Use Disorder treatment organization, and will inform a future scaled-up implementation.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Boulder Care | Portland | Oregon | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07169409 on ClinicalTrials.gov ↗ ← All trials in the USA